Background Many observational studies highlight clonal haematopoiesis (CH) as a novel determinant of cardiovascular disease ...
In a phase 2b trial, danicamtiv, a novel cardiac myosin activator, was well tolerated and associated with improved heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback